Jindřich Špinar - Concepedia

Author

Jindřich Špinar

Also Known As

Boris Starcevic, H. Kanamori, J Spinar, J Špinar, J. Spinar, J. ŠPINAR, J. Špinar, JINDRICH SPINAR, Jindrich Spinar, Jindřich Spinar

864

Publications

7.1K

Citations

H-Index

Concepts

All Affiliations

Masaryk University University Hospital Brno Brigham and Women's Hospital Université Paris Cité Thrombolysis in Myocardial Infarction Study Group

JŠ

About

Jindřich Špinar is an author at Masaryk University specializing in medicine, cardiology, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	10	745
2	Public Health	3	3	321
3	Emergency Medicine	3	3	102
4	Diabetes	1	2	188
5	Immunology	1	1	10

Jindřich Špinar

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Edoxaban versus Warfarin in Patients with Atrial Fibrillation Robert P. Giugliano, Christian T. Ruff, Eugene Braunwald, New England Journal of Medicine	2013	5K
Effects of Serelaxin in Patients with Acute Heart Failure Marco Metra, John R. Teerlink, Gad Cotter, New England Journal of Medicine	2019	253
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial Andreas Goette, José Luís Merino, Michael D. Ezekowitz, The Lancet ThrombosisCardiovascular DiseasePharmacologyCardiovascular PharmacologyPharmacotherapy	2016	243
Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin I Marc P. Bonaca, Benjamin M. Scirica, Marc S. Sabatine, Journal of the American College of Cardiology CardiomyopathyHeart FailureCardiovascular DiseaseImproved Assay PerformanceCardiac Troponin	2010	134
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi, The Lancet ObesityMetabolic SyndromeCamellia-timi 61Diabetes ManagementDiabetes	2018	94
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation Christian T. Ruff, Siddharth M. Patel, Robert P. Giugliano, New England Journal of Medicine	2025	82
Right ventricular myocardial infarction: From pathophysiology to prognosis. Tomáš Ondrúš, Jan Kaňovský, Tomáš Novotný, PubMed From PathophysiologyHeart FailureCardiogenic ShockCardiovascular DiseaseCardiac Physiology	2013	62
Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients Jiří Pařenica, Jiří Jarkovský, Jan Maláska, Shock	2016	57
Two MMP-2 Promoter Polymorphisms (–790T/G and –735C/T) in Chronic Heart Failure Anna Vašků, Monika Pávková Goldbergová, Lýdie Izakovičová Hollá, Clinical Chemistry and Laboratory Medicine (CCLM)	2003	35
Kinetics of procalcitonin, C-reactive protein and interleukin-6 in cardiogenic shock – Insights from the CardShock study Anu Kataja, Tuukka Tarvasmäki, Johan Lassus, International Journal of Cardiology InflammationCardiogenic ShockCardiovascular DiseasePhysiologyCardshock Study	2020	33

Page 1